Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2014

View Archived Issues

Anti-LFA-1A antibody with utility for targeting alloreactive T cells in kidney allografts

Astellas Pharma profiles pipeline developments of first quarter of fiscal 2014

Daya Drug Discoveries profiles novel non-opioid, non-cannabinoid analgesic

ANI Pharmaceuticals acquires vancomycin assets from Shire

Bristol-Myers Squibb forms joint venture to advance development of U.S. academic discoveries

Ignyta licenses two first-in-class kinase inhibitors from Nerviano

Evolva acquires Prosarix

Cellular Biomedicine Group to acquire Agreen Biotech

Regen BioPharma advances development of dCellVax

Conditional marketing authorization in E.U. for Translarna in Duchenne muscular dystrophy

T-923 enhances the efficacy of CoB-based strategies and promotes transplant tolerance

Novel MAbs for cancer disclosed by Metheresis Translational Research

Merck KGaA prepares new cathepsin D inhibitors

New heterocyclic compounds patented by group in China

Lupin divulges novel nAChR alpha7 modulators

Yuhan reports novel glucokinase activators

NanoViricides to restart anti-Ebola virus drug program

AB-103 granted orphan product status in the E.U. for soft tissue infections

Neuraceq launched in Germany

Phase III ASPIRE trial of Kyprolis meets primary endpoint

Aegis Therapeutics seeks partnering for exenatide nasal spray

Octapharma's Nuwiq receives E.U. approval for hemophilia A

Moerae Matrix begins phase I trial of MMI-0100 for idiopathic pulmonary fibrosis

Novimmune completes phase I trial of NI-0101

Rogne Bioscience in-licenses anti-inflammatory peptide for development as psoriasis drug

Japanese approval sought for monotherapy use of E Keppra Intravenous Drip Infusion

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...